Sorrento Therapeutics Inc... (SRNE)
Sorrento Therapeutics Statistics
Share Statistics
Sorrento Therapeutics has 551.28M shares outstanding. The number of shares has increased by 0.62% in one year.
| Shares Outstanding | 551.28M |
| Shares Change (YoY) | 0.62% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 0.02% |
| Shares Floating | 542.68M |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 64.56M, so 11.71% of the outstanding shares have been sold short.
| Short Interest | 64.56M |
| Short % of Shares Out | 11.71% |
| Short % of Float | 11.9% |
| Short Ratio (days to cover) | 4.96 |
Valuation Ratios
The PE ratio is -0.01 and the forward PE ratio is null. Sorrento Therapeutics's PEG ratio is 0.
| PE Ratio | -0.01 |
| Forward PE | n/a |
| PS Ratio | 0.06 |
| Forward PS | null |
| PB Ratio | -0.2 |
| P/FCF Ratio | -0.01 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Sorrento Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.29, with a Debt / Equity ratio of -7.23.
| Current Ratio | 0.29 |
| Quick Ratio | 0.26 |
| Debt / Equity | -7.23 |
| Total Debt / Capitalization | 116.05 |
| Cash Flow / Debt | -2.18 |
| Interest Coverage | -58.82 |
Financial Efficiency
Return on equity (ROE) is 30.79% and return on capital (ROIC) is -445.03%.
| Return on Equity (ROE) | 30.79% |
| Return on Assets (ROA) | -1.21% |
| Return on Capital (ROIC) | -445.03% |
| Revenue Per Employee | $66,216.02 |
| Profits Per Employee | $-603,628.03 |
| Employee Count | 949 |
| Asset Turnover | 0.13 |
| Inventory Turnover | 3.35 |
Taxes
| Income Tax | -2.42M |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 1.68, so Sorrento Therapeutics's price volatility has been higher than the market average.
| Beta | 1.68 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0 |
| 200-Day Moving Average | 0 |
| Relative Strength Index (RSI) | 47.96 |
| Average Volume (20 Days) | - |
Income Statement
In the last 12 months, Sorrento Therapeutics had revenue of 62.84M and earned -572.84M in profits. Earnings per share was -1.37.
| Revenue | 62.84M |
| Gross Profit | 29.39M |
| Operating Income | -504.31M |
| Net Income | -572.84M |
| EBITDA | -539.93M |
| EBIT | -504.31M |
| Earnings Per Share (EPS) | -1.37 |
Balance Sheet
The company has 23.63M in cash and 134.5M in debt, giving a net cash position of -110.87M.
| Cash & Cash Equivalents | 23.63M |
| Total Debt | 134.5M |
| Net Cash | -110.87M |
| Retained Earnings | -1.96B |
| Total Assets | 456.69M |
| Working Capital | -131.84M |
Cash Flow
In the last 12 months, operating cash flow was -293.86M and capital expenditures -13.66M, giving a free cash flow of -307.51M.
| Operating Cash Flow | -293.86M |
| Capital Expenditures | -13.66M |
| Free Cash Flow | -307.51M |
| FCF Per Share | -0.73 |
Margins
Gross margin is 46.77%, with operating and profit margins of -802.55% and -911.6%.
| Gross Margin | 46.77% |
| Operating Margin | -802.55% |
| Pretax Margin | -893.95% |
| Profit Margin | -911.6% |
| EBITDA Margin | -859.22% |
| EBIT Margin | -802.55% |
| FCF Margin | -489.37% |
Dividends & Yields
SRNE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for SRNE.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Aug 1, 2013. It was a backward split with a ratio of 1:25.
| Last Split Date | Aug 1, 2013 |
| Split Type | backward |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | -10.88 |
| Piotroski F-Score | 3 |